Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial

BACKGROUND: COVID-19 can lead to multiorgan failure. Dapagliflozin, a SGLT2 inhibitor, has significant protective benefits for the heart and kidney. We aimed to see whether this agent might provide organ protection in patients with COVID-19 by affecting processes dysregulated during acute illness. M...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Lancet Diabetes Endocrinol
Autors principals: Kosiborod, Mikhail N, Esterline, Russell, Furtado, Remo H M, Oscarsson, Jan, Gasparyan, Samvel B, Koch, Gary G, Martinez, Felipe, Mukhtar, Omar, Verma, Subodh, Chopra, Vijay, Buenconsejo, Joan, Langkilde, Anna Maria, Ambery, Philip, Tang, Fengming, Gosch, Kensey, Windsor, Sheryl L, Akin, Emily E, Soares, Ronaldo V P, Moia, Diogo D F, Aboudara, Matthew, Hoffmann Filho, Conrado Roberto, Feitosa, Audes D M, Fonseca, Alberto, Garla, Vishnu, Gordon, Robert A, Javaheri, Ali, Jaeger, Cristiano P, Leaes, Paulo E, Nassif, Michael, Pursley, Michael, Silveira, Fabio Serra, Barroso, Weimar Kunz Sebba, Lazcano Soto, José Roberto, Nigro Maia, Lilia, Berwanger, Otavio
Format: Artigo
Idioma:Inglês
Publicat: Elsevier Ltd. 2021
Matèries:
Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8294807/
https://ncbi.nlm.nih.gov/pubmed/34302745
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S2213-8587(21)00180-7
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars